Cardiovascular Systems recently announced that it has partnered with Chansu Vascular Technologies to develop a new drug-coated balloon technology.
Through the partnership, Cardiovascular Systems and Chansu Vascular Technologies will develop peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems will provide milestone-based financing to Chansu Vascular Technologies for the development of the drug-coated balloons. The deal also includes an acquisition option agreement in which Cardiovascular Systems will have exclusive rights and obligations to acquire the company upon completion of key technical and clinical milestones in the development program.
“This partnership is consistent with our strategic vision to develop an innovative portfolio of new products. We believe these next generation DCBs will complement our current and growing portfolio of products for the treatment of complex coronary and peripheral disease. We are thrilled to be working with CVT in this partnership and are extremely confident that Dr. Marco and his team’s extensive past DCB experience will prove invaluable in developing these next generation DCBs,” Cardiovascular Systems’s chief medical officer Ryan Egeland said in a news release.
Drug-coated balloons are used as a percutaneous interventional treatment option for femora-popliteal lesions in patients who have peripheral artery disease. The balloons are also increasingly recognized for their potential in complex coronary artery disease, according to Cardiovascular Systems. They can be used in in-stent restenosis, small vessels and bifurcation lesions for sustained anti-restenotic efficacy without the limitations of permanent implants.
The active drug (Everolimus) in Chansu Vascular Technologies’s drug coated balloon technology acts as a cytostatic agent to reduce tissue hyperplasia and associated restenosis. It has a proven history of safety and efficacy in coronary drug-eluting stent applications, according to the company.
“The CVT DCBs will be designed to capitalize on the proven long-standing anti-restenotic benefits of everolimus for the treatment of patients with cardiovascular lesions. This collaboration enables us to develop a new class of DCBs that we believe will improve patient outcomes,” Chansu Vascular Technologies founder Philippe Marco said.
